Seelos Therapeutics, Inc. stock is down -73.88% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.17% of the previous 28 December’s closed higher than November.
Seelos Therapeutics, Inc. focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the. treatment of acute suicidal ideation and behavior in patients with major depressive disorders.